Genetic Analysis AS (XSAT:GEAN) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:GEAN Genetic Analysis AS XSAT:GEAN
34 GF Score
Price kr0.66
GF Value kr0.54
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Genetic Analysis AS Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XSAT:GEAN vs TMO, DHR, IDXX: Short Interest Comparison

For the Diagnostics & Research subindustry, Genetic Analysis AS's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Analysis AS Short Interest vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's Short Interest distribution charts can be found below:

* The bar in red indicates where Genetic Analysis AS's Short Interest falls into.


XSAT:GEAN
34GF Score
Genetic Analysis AS XSAT:GEAN
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genetic Analysis AS (XSAT:GEAN) Overvalued in 2026?

Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued. The current stock price of kr0.66 is trading 22.2% above its estimated GF Value™ of kr0.54. GuruFocus considers Genetic Analysis AS to be Modestly Overvalued.

Key valuation signals for XSAT:GEAN:

  • Short Interest:
  • GF Value™: kr0.54 vs. price of kr0.66 (22.2% above fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the XSAT:GEAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genetic Analysis AS Business Description

Other Exchanges 8V8:Germany
Address Ulvenveien 80, Oslo, NOR, 0581
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score

Get the complete analysis for XSAT:GEAN

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.66
Price
kr0.54
GF Value